Dr. Zhang completed her medical education at Beijing Medical University and Capital Medical University.

She entered the pharmaceutical industry 12 years ago when a central lab set up the first anatomic pathology (AP) department in China.

Dr. Zhang’s oncology drug development journey began with a breast cancer study, followed by various tumor studies including NSCLC, GC, CRC, UC, DLBCL, etc. as well as many companion diagnostic studies.

The customers were top-30 global pharmaceutical companies with a gradual increasing presence of domestic Chinese companies.